We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Cervical Cancer Exams Proposed for Low-Resource Settings

By Labmedica staff writers
Posted on 12 Mar 2008
Cervical cancer, caused by the human papillomavirus (HPV), affects about 500,000 women each year and kills 270,000 worldwide annually. More...
There is a huge discrepancy between cervical cancer deaths in rich and poor nations--80-85% of deaths occur in the developing world. In developed countries, screening programs using the Pap smear are in place to spot disease and treat it early. However, a successful Pap testing program requires a high degree of organization, sophisticated laboratory equipment, and highly trained technicians. In spite of government efforts, large-scale Pap screening programs have failed in poorer regions.

During a panel presentation at the Goethe-Institut (Washington, DC, USA) on March 5, 2008, Dr. Jacqueline Sherris of PATH (formally: Program for Appropriate Technology in Health), an Alliance for Cervical Cancer Prevention (ACCP) founder, noted, "cervical cancer represents a huge global inequity with a heavy burden on poor women.”

A painless visual screening method has been found to be as effective, if not more effective, as the Pap smear. For the visual screening method, a trained health worker swabs the patient's cervix with vinegar. After one minute, any small lesions on the cervix--signs of potential future cancer--can be seen with the naked eye.

"In most cases it is possible to treat women for precancer during the same visit to the clinic,” said Dr. Harshad Sanghvi of the Johns Hopkins Program for International Education in Gynecology and Obstetrics (JHPIEGO; Baltimore, MD, USA), an ACCP partner. "This is important because if a woman is sent home the day of the exam and asked to come back days or weeks later to hear the results and be treated, she may not be able to return. In the past, many women have missed the care they needed for this reason. Treatment in the late stages of cervical cancer--when women suffer symptoms--is difficult and often not successful. We need to screen all women, beginning at age 30, and provide rapid treatment to those who need it,” Dr. Sanghvi added.

Dr. R. Sankaranarayanan, from the International Agency for Research on Cancer (IARC; Lyons, France), has studied alternatives to Pap smear screening in India and other countries. He explained that cervical cancer is easy to treat if precancerous signs are detected early. Treatment in low-resource settings often can be implemented using a device that destroys the affected tissue by freezing, the same way that common warts are frozen.

"New technologies for cervical cancer prevention are revolutionizing public health,” stated Silvana Luciani of the Pan American Health Organization (PAHO; Washington, DC, USA). "Visual screening methods, high-tech DNA tests for HPV, and the new HPV vaccines represent incredible opportunities to strengthen prevention. We need to protect girls from HPV infection with vaccine, but immunization is not a substitute for screening.

Screening programs are needed to care for women who may have already been infected with HPV, because the vaccine does not protect them effectively and there are cancer-causing types of HPV not targeted by the vaccine. Research indicates that a combination of vaccination and screening can dramatically reduce cervical cancer deaths in the coming decades.”


Related Links:
Goethe-Institut
Johns Hopkins Program for International Education in Gynecology and Obstetrics
International Agency for Research on Cancer

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.